About SINTX
SINTX is a publicly listed company based in Salt Lake City (United States) founded in 1996. Silicon nitride medical devices are manufactured for interbody fusion. SINTX has raised $22.13 million across 17 funding rounds from investors including NIH, HHS and Oxford Finance. The company has 20 employees. SINTX has completed 1 acquisition, including Technology Assessment & Transfer. Its chief executive, as recorded, is B. Sonny Bal. SINTX offers products and services including Silicon Nitride Industrial (STX-100), Silicon Nitride Biomedical (FleX-SN), and Composite 3D Printing. Its focus areas include High Tech, Advanced Materials, Biomaterials and Biomimetics. Its legal entity is SINTX Technologies, Inc. Its competitors include RevBio, ParaGen Technologies and Avisi Technologies; 3 of its 3 listed competitors have raised funding.
Company details
SINTX was founded in 1996 and is based in Salt Lake City, United States. Operations center on the medical devices sector, where interbody fusion devices are produced from medical-grade silicon nitride. Bone growth is facilitated by a nano surface texture, and the materials strength exceeds that of bone. Imaging capabilities and antibacterial properties are incorporated to address clinical requirements in spinal applications.
- Annual Revenue$1.02 M (USD)-64.74as on Dec 31, 2025
- Net Profit-$10.36 M (USD)5.99as on Dec 31, 2025
- EBITDA-$10.06 M (USD)-31.42as on Dec 31, 2025
- Total Equity Funding$22.13M (USD)
in 17 rounds
- Latest Funding Round$5M (USD), Post-IPO
Feb 2025
- InvestorsNIH
& 4 more
- Employee Count20
- Investments & Acquisitions
Products & Services of SINTX
SINTX offers a comprehensive portfolio of products and services, including Silicon Nitride Industrial (STX-100), Silicon Nitride Biomedical (FleX-SN), and Composite 3D Printing.
Hard, corrosion-resistant ceramic for industrial and high-temperature applications.
Ceramic with antibacterial properties for medical implants and devices.
Service for transforming concepts into printed parts using advanced ceramics.
Apps and channels of SINTX
its YouTube channel Sintx Technologies has 119 subscribers and 3 videos.
Videos from SINTX
The most watched videos on SINTX's YouTube channel, Sintx Technologies (119 subscribers). Click a video to play it here.
More on Sintx Technologies.
Funding Insights of SINTX
SINTX has successfully raised a total of $22.13M across 17 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $22.13M
- Total Rounds 17
- Last Round Post-IPO — $5M
- Investors Count 5
Latest 10 of 17 funding rounds of SINTX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2025 | $5M | Post-IPO | – | – | – |
| Oct 2023 | $1.97M | Grant | – | – | |
| Sep 2022 | $227,140 | Grant | – | – | |
| Mar 2022 | $300,000 | Grant | – | – | |
| Sep 2021 | $1.52M | Grant | – | – | |
| Sep 2015 | $15M | Unspecified | – | – | – |
| Jul 2014 | $26M | Debt – Venture | – | – | – |
| Jun 2014 | $5.55M | Unspecified | – | – | – |
| Sep 2013 | $9.48M | Unspecified | – | – | – |
| Apr 2013 | $3.13M | Unspecified | – | – | – |
5 investors in total: 5 institutional.
Investors in SINTX
SINTX has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
| evermoreinvestments.com | ||||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Zions Bank provides private banking and wealth management services for high-net-worth individuals and families. | 1873 | zionsbank.com | Salt Lake City, United States |
Investor details for SINTX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SINTX
1 people are tracked at SINTX (1 in leadership); the tracked headcount is 20.
| Name | Role | Group |
|---|---|---|
B. Sonny Bal | CEO & President | Leadership |
Complete people profiles for SINTX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of SINTX
SINTX is a publicly listed company on the NASDAQ with ticker symbol SINT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Jan 2023
- Listed onLSE: 0A8S
- Listed entitySiNtx Technologies, Inc.
- Exchange sectorHealth technology
- ISINUS8293927039
- Share price$2.07 (-2.82% on the day) · 2026-10-13
- Market capitalisation$15.6M
- EPS (diluted, trailing year)$-5.47
- Volume (last session)36,892
Financials of SINTX
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.0M | -$10.4M | -$10.1M |
| 2024 | $2.9M | -$11.0M | -$7.7M |
| 2023 | $2.6M | -$8.3M | -$11.7M |
| 2022 | $1.6M | -$12.0M | -$10.4M |
| 2021 | $606,000 | -$9.3M | -$10.0M |
Detailed financial statements for SINTX
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SINTX
SINTX has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Technology Assessment & Transfer.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of metal services | techassess.com | United States | 1983 | Jul 2022 | •••• |
Complete acquisition details for SINTX
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of SINTX
5 dated milestones of SINTX across 29 years, from founding to its latest funding, stage changes and deals.
- Founded SINTX is founded.
- Funding First funding round.
- Acquisition Acquires Technology Assessment & Transfer.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $5.0M.
Competitors of SINTX
SINTX has 3 listed competitors in our database, 3 of them funded. They include RevBio, ParaGen Technologies and Avisi Technologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revbio.com | 2014 | Lowell, United States | $24.42M | Synthetic adhesives for bone and dental repair are developed. | ||
| paragentechnologies.com | 2016 | Columbus, United States | $11.64M | 1 | Tissue engineering technologies are developed with synthetic nanofiber scaffolds. | |
| avisitech.com | 2017 | Philadelphia, United States | $5M | Nano-materials for glaucoma treatment implants are developed. |
Detailed competitors of SINTX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SINTX
The website of SINTX (sintx.com) receives about 3.7K visits a month.
- Monthly visits3.7K
▼ 13.3% vs previous month
Top companies in Battery & Advanced Material Systems
3 companies that operate in the same segment as SINTX (Battery & Advanced Material Systems) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
AI and app-based smart windows are provided for buildings. | 2007 | Milpitas, California, United States | USD 3.01 B | USD 101.33 M | 410 | |
Aerogel-based thermal insulation solutions are provided for energy conservation. | 2001 | United States | USD 198.35 M | USD 271.1 M | 554 | |
Mycelium-based leather alternative fabrics are manufactured and provided. | 2009 | Emeryville, California, United States | USD 219.4 M | USD 1.37 M | 22 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sintx
Complete news archive for SINTX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SINTX
SINTX was founded in 1996 and raised its 1st funding round 7 years after it was founded.
SINTX is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
B. Sonny Bal is the CEO of SINTX, as recorded in our data.
SINTX is a funded company, having raised a total of $22.13M across 17 funding rounds to date. The company's 1st funding round was a Unspecified of $3.13M, raised on Dec 2003.
SINTX has 20 employees.
Annual revenue of SINTX is $1.02M as on Dec 31, 2025.
SINTX was founded in 1996 and is based in Salt Lake City, United States. Operations center on the medical devices sector, where interbody fusion devices are produced from medical-grade silicon nitride. Bone growth is facilitated by a nano surface texture, and the materials strength exceeds that of bone. Imaging capabilities and antibacterial properties are incorporated to address clinical requirements in spinal applications.
SINTX's top competitors include RevBio, Avisi Technologies and ParaGen Technologies.
SINTX offers Silicon Nitride Industrial (STX-100), Silicon Nitride Biomedical (FleX-SN), and Composite 3D Printing.
Yes, SINTX is publicly traded on NASDAQ under the ticker symbol SINT.
SINTX has made 1 acquisition, including Technology Assessment & Transfer.
SINTX has 5 investors. Key investors include NIH, HHS, Oxford Finance, Zions Bank, and Evermore Investments.